Regeneron Pharmaceuticals (REGN) Change in Accured Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at $107.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 150.3% year-over-year to $107.7 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 157.88% YoY), while the FY2025 annual figure was $736.8 million, changed 0.23% from the prior year.
• Change in Accured Expenses was $107.7 million for Q1 2026 at Regeneron Pharmaceuticals, up from -$24.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $759.2 million in Q3 2025 to a low of -$250.4 million in Q1 2022.
• Historically, Change in Accured Expenses has averaged $120.0 million across 5 years, with a median of $110.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses plunged 621.61% in 2022, then soared 460.95% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $347.6 million in 2022, then tumbled by 139.9% to -$138.7 million in 2023, then surged by 262.65% to $225.6 million in 2024, then plunged by 110.95% to -$24.7 million in 2025, then soared by 536.03% to $107.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $107.7 million (Q1 2026), -$24.7 million (Q4 2025), and $759.2 million (Q3 2025), per Business Quant data.